SEC Form 4 · accession 0000899243-18-023257
BIODELIVERY SCIENCES INTERNATIONAL INC · BDSI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Todd C Davis
Director
Period of report
Aug 24, 2018
Accepted (ET)
Aug 24, 2018 · 6:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001103021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 24, 2018 | C | 416,667 | $0.00 | A | 419,791 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Convertible Preferred StockF1 | $1.80 | Aug 24, 2018 | C | 75 | D | — | — | Common Stock | 416,667 | 0 | D |
Explanation of responses
- F1The Series B Non-Voting Convertible Stock ("Series B") became convertible upon shareholder approval of an increase of the Company's authorized number of shares issued and outstanding on August 2, 2018. The Series B does not have an expiration date, but the issuer may force conversion of the Series B, subject to certain limitations.